The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Effect of Aspirin on All-Cause Mortality in the Healthy Elderly
Open accessAbstract
BACKGROUND: In the primary analysis of the Aspirin in Reducing Events in the Elderly (ASPREE) trial, now published in the Journal, we report that the daily use of aspirin did not provide a benefit with regard to the primary end point of disability-free survival among older adults. A numerically higher rate of the secondary end point of death from any cause was observed with aspirin than with placebo. METHODS: From 2010 through 2014, we enrolled community-dwelling persons in Australia and the United States who were 70 years of age or older (or ≥65 years of age among blacks and Hispanics in the United States) and did not have cardiovascular disease, dementia, or disability. Participants were randomly assigned to receive 100 mg of enteric-coated aspirin or placebo. Deaths were classified according to the underlying cause by adjudicators who were unaware of trial-group assignments. Hazard ratios were calculated to compare mortality between the aspirin group and the placebo group, and post hoc exploratory analyses of specific causes of death were performed. RESULTS: Of the 19,114 persons who were enrolled, 9525 were assigned to receive aspirin and 9589 to receive placebo. A total of 1052 deaths occurred during a median of 4.7 years of follow-up. The risk of death from any cause was 12.7 events per 1000 person-years in the aspirin group and 11.1 events per 1000 person-years in the placebo group (hazard ratio, 1.14; 95% confidence interval [CI], 1.01 to 1.29). Cancer was the major contributor to the higher mortality in the aspirin group, accounting for 1.6 excess deaths per 1000 person-years. Cancer-related death occurred in 3.1% of the participants in the aspirin group and in 2.3% of those in the placebo group (hazard ratio, 1.31; 95% CI, 1.10 to 1.56). CONCLUSIONS: Higher all-cause mortality was observed among apparently healthy older adults who received daily aspirin than among those who received placebo and was attributed primarily to cancer-related death. In the context of previous studies, this result was unexpected and should be interpreted with caution. (Funded by the National Institute on Aging and others; ASPREE ClinicalTrials.gov number, NCT01038583 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw106 · Cited by 6,457
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Antman, E., Bassand, J.-P., Klein, W., Ohman, M., Lopez Sendon, J. L., Rydén, L., Simoons, M., & Tendera, M. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00804-4 · Cited by 4,821
Final Report on the Aspirin Component of the Ongoing Physicians' Health Study
Steering Committee of the Physicians' Health Study Research Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198907203210301 · Cited by 2,264
A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women
Ridker, P. M., Cook, N. R., Lee, I.-M., Gordon, D., Gaziano, J. M., Manson, J. E., Hennekens, C. H., & Buring, J. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050613 · Cited by 1,945
Rothwell, P. M., Fowkes, F. G. R., Belch, J. F., Ogawa, H., Warlow, C. P., & Meade, T. W. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62110-1 · Cited by 1,497
Randomised trial of prophylactic daily aspirin in British male doctors
Peto, R., Gray, R., Collins, R., Wheatley, K., Hennekens, C., Jamrozik, K., Warlow, C., Hafner, B., Thompson, E., Norton, S., et al. (1988) · BMJ · doi:10.1136/bmj.296.6618.313 · Cited by 1,166
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly
McNeil, J. J., Wolfe, R., Woods, R. L., Tonkin, A. M., Donnan, G. A., Nelson, M. R., Reid, C. M., Lockery, J. E., Kirpach, B., Storey, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805819 · Cited by 1,139
Self-citation
Cited by
Inflammation and aging: signaling pathways and intervention therapies
Li, X., Li, C., Zhang, W., Wang, Y., Qian, P., & Huang, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01502-8 · Cited by 1,443
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly
McNeil, J. J., Wolfe, R., Woods, R. L., Tonkin, A. M., Donnan, G. A., Nelson, M. R., Reid, C. M., Lockery, J. E., Kirpach, B., Storey, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805819 · Cited by 1,139
Self-citationEffect of aspirin on disability-free survival in the healthy elderly
McNeil, J. J., Woods, R. L., Nelson, M. R., Reid, C. M., Kirpach, B., Wolfe, R., Storey, E., Shah, R. C., Lockery, J. E., Tonkin, A. M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800722 · Cited by 590
Self-citationZheng, S. L., & Roddick, A. J. (2019) · JAMA · doi:10.1001/jama.2018.20578 · Cited by 577
The quest to slow ageing through drug discovery
Partridge, L., Fuentealba, M., & Kennedy, B. K. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0067-7 · Cited by 468
Koo, B.-K., Kang, J., Park, K. W., Rhee, T.-M., Yang, H.-M., Won, K.-B., Rha, S.-W., Bae, J.-W., Lee, N. H., Hur, S.-H., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01063-1 · Cited by 370
Targeting cancer-promoting inflammation — have anti-inflammatory therapies come of age?
Hou, J., Karin, M., & Sun, B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00459-9 · Cited by 366
Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women
Cho, L., Davis, M., Elgendy, I., Epps, K., Lindley, K. J., Mehta, P. K., Michos, E. D., Minissian, M., Pepine, C., Vaccarino, V., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.060 · Cited by 347
Bacteria in cancer initiation, promotion and progression
El Tekle, G., & Garrett, W. S. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00594-2 · Cited by 343
Vitamin D testing and treatment: a narrative review of current evidence
Pilz, S., Zittermann, A., Trummer, C., Theiler-Schwetz, V., Lerchbaum, E., Keppel, M. H., Grübler, M. R., März, W., & Pandis, M. (2019) · Endocrine Connections · doi:10.1530/ec-18-0432 · Cited by 276
Ten things to know about ten cardiovascular disease risk factors
Bays, H. E., Taub, P. R., Epstein, E., Michos, E. D., Ferraro, R. A., Bailey, A. L., Kelli, H. M., Ferdinand, K. C., Echols, M. R., Weintraub, H., et al. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2021.100149 · Cited by 274
Colonoscopy screening and surveillance guidelines
Saito, Y., Oka, S., Kawamura, T., Shimoda, R., Sekiguchi, M., Tamai, N., Hotta, K., Matsuda, T., Misawa, M., Tanaka, S., et al. (2021) · Digestive Endoscopy · doi:10.1111/den.13972 · Cited by 170
Diabetes and Cardiovascular Disease: an Update
Almourani, R., Chinnakotla, B., Patel, R., Kurukulasuriya, L. R., & Sowers, J. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1239-x · Cited by 114
Berk, M., Woods, R. L., Nelson, M. R., Shah, R. C., Reid, C. M., Storey, E., Fitzgerald, S., Lockery, J. E., Wolfe, R., Mohebbi, M., et al. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.1214 · Cited by 89
Self-citationThe importance of long-term follow up of participants in clinical trials
Cuzick, J. (2023) · British Journal of Cancer · doi:10.1038/s41416-022-02038-4 · Cited by 101
Adverse events in older adults and the risk of dementia and cognitive decline
Nilaweera, D., Gurvich, C., Freak-Poli, R., Woods, R., Owen, A., Murray, A., Orchard, S. G., Britt, C., Wu, Z., McNeil, J., et al. (2023) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2023.100592 · Cited by 21
Self-citationChuang, M.-C., Yang, Y.-H., Hsieh, M.-J., Lin, Y.-C., Yang, T.-M., Chen, P.-C., & Hung, M.-S. (2021) · BMC Cancer · doi:10.1186/s12885-021-08999-8 · Cited by 9
“Moreover, the results of the Aspirin in Reducing Events in the Elderly trial showed an increased risk of cancer-related mortality in the aspirin group [14].”
ResultHierarchical endpoints and win statistics for geromedicine trials
Abdellatif, M., Kim, Y., & Kroemer, G. (2026) · Nature Aging · doi:10.1038/s43587-026-01158-3
Metadata
- Authors
- McNeil, J. J., Nelson, M. R., Woods, R. L., Lockery, J. E., Wolfe, R., Reid, C. M., Kirpach, B., Shah, R. C., Ives, D. G., Storey, E., Ryan, J., Tonkin, A. M., Newman, A. B., Williamson, J. D., Margolis, K. L., Ernst, M. E., Abhayaratna, W. P., Stocks, N., Fitzgerald, S. M., Orchard, S. G., Trevaks, R. E., Beilin, L. J., Donnan, G. A., Gibbs, P., Johnston, C. I., Radziszewska, B., Grimm, R., & Murray, A. M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-10-18
- Volume
- 379
- Issue
- 16
- Pages
- 1519-1528
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2889884522
- Cited by
- 813
- References
- 58
- FWCI
- 73.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.